AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03054857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
Study NCT02057471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Description: 1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
Study NCT02482987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dense polytetrafluoroethylene (dPTFE) membrane Cytoplast
Description: ridge preservation intervention using the dPTFE membrane device
Study NCT02482987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: human amniotic-tissue derived membrane BioXclude
Description: ridge preservation intervention using the dPTFE membrane device
Study NCT02482987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Preservation with overlay graft
Description: ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
Study NCT02482987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Preservation without overlay graft
Description: ridge preservation without overlay graft / traditional FDBA placement into the socket only
Study NCT02389998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Suspension
Description: The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
Study NCT02389998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyoscyamine
Description: While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
Study NCT02389998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscyamine
Description: While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
Study NCT00373867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Treatment-based classification physical therapy
Study NCT00373867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graded exercise
Description: Graded exercise increases an individual's tolerance to activity over time
Study NCT00373867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded exposure
Description: Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
Study NCT02428413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ISO-Gard Mask
Description: to scavenge waste anesthetic gases from patients and provide supplemental oxygen
Study NCT02428413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen mask
Description: Provide supplemental oxygen
Study NCT04496661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation
Description: Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
Study NCT04496661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation
Description: Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
Study NCT04496661 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS and PES
Description: For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
Study NCT02925741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silk-Like Linens
Description: Synthetic moisture-wicking fabric
Study NCT01248871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: procedure:sevoflurane-remifentanil/sufentanil
Description: Active Comparator
Study NCT00379626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cognitive and hormone treatment
Description: cognitive and hormone (Leuprorelin) treatment
Study NCT03034720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
Study NCT03644199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT) assessment arm
Description: Hormonal and motility responses to a standard OGTT evaluation arm
Study NCT03644199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mixed meal test evaluation test arm
Description: Evaluate the hormonal and motility responses to a standard mixed meal test through the day
Study NCT00746993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured contraceptive counseling
Description: Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
Study NCT02424968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Nodal Irradiation
Description: Undergo TLI
Study NCT05028465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Papillectomy
Description: A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
Study NCT05028465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobiliary Radiofrequency Ablation
Description: The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
Study NCT00691691 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
Study NCT04377191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergame
Description: Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
Study NCT04377191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergame
Description: ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
Study NCT04377191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
Study NCT04377191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
Study NCT01976507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate mesylate
Description: Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
Study NCT02858115 — intervention group
Intervention type: OTHER
Intervention: Fluid challenge
Description: 100 ml of crystalloid was infused over 1-min
Study NCT01248871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: volatile agent only during reperfusion
Description: Active Comparator
Study NCT01248871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-remifentanil/sufentanil
Description: Active Comparator
Study NCT02858115 — intervention group
Intervention type: OTHER
Intervention: Trans-oesophageal echography
Description: an echocardiographic assessment at 1-min,
Study NCT02959411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
Study NCT02959411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care diuretic therapy
Description: Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
Study NCT02684032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
Study NCT04068792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RSV Mobile Application
Description: Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
Study NCT04068792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
Study NCT04068792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 2.5 mg/kg
Description: JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
Study NCT04068792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 3 mg/kg
Description: JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
Study NCT02684032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
Study NCT02684032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole at 2.5 mg daily
Study NCT02684032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
Study NCT02067689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp
Study NCT04068792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 4.5 mg/kg
Description: JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
Study NCT01029704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001442
Description: Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days.
Study NCT01029704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules to match EGT0001442
Description: Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.
Study NCT04440540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: lifestyle changes supervised by dietitians
Study NCT04440540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional care (control)
Description: receive routine care
Study NCT00840931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
Study NCT00840931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bystander vaccine
Description: In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
Study NCT03294343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingo-oophorectomy only by laparoscopy
Description: Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
Study NCT03294343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingo-oophorectomy with hysterectomy by laparoscopy
Description: Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
Study NCT03183804 — intervention group
Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
Study NCT03183804 — intervention group
Intervention type: OTHER
Intervention: Standard therapy
Description: Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
Study NCT04775732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: infliximab therapeutic drug monitoring
Description: dose optimization of infliximab based on a predefined dosing algorithm
Study NCT04775732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab therapeutic drug monitoring
Description: dose optimization of infliximab based on a predefined dosing algorithm
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOYC
Description: FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal for it (GFI)
Description: GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wonderous Wetlands
Description: Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
Study NCT01688908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Screening
Description: 1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions.
Study NCT02725190 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleepless night
Description: Each subject will undergo 28 hours of sleep deprivation.
Study NCT02725190 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Normal sleep night
Description: Normal sleep at home before trial.
Study NCT03463668 — intervention group
Intervention type: DEVICE
Intervention: uncovered metal duodenal prosthesis
Description: Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
Study NCT03699137 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT04738630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT00647660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
Description: 80/5mg, single dose fasting
Study NCT00647660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corzide® Tablets 80 mg/5 mg
Description: 80/5mg, single dose fasting
Study NCT01497613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM C: Computer Condition
Description: A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
Study NCT01497613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRISM B: Notebook Condition
Description: Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.